61. Ingenta: Article Summary -- Antigen Presentation In Graft-vs-host Disease Antigen presentation in graftvs-host disease Experimental Hematology December 2003, vol. 31, no. 12, pp. 1187-1197(11) Shlomchik http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=pubinfobike://els/

62. Ingenta: Article Summary -- Lichenoid Graft Vs. Host Disease Following Liver Tra Lichenoid graft vs. host disease following liver transplantation Journal of Cutaneous Pathology February 2004, vol. 31, no. 2, pp. http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=pubinfobike://mksg

63. Clinical Tissue Transplantation For example, failure of liver transplants is more often due to vascular complications and blood seepage than from rejection. graft vs. host disease. http://www.ufrgs.br/favet/imunovet/immuno/ch13/grafhost.htm

Clinical Tissue Transplantation Organ and tissue transplantation has advanced from an experimental procedure used only in life-threatening, emergency procedures to the treatment of choice for a wide range of clinical conditions. It includes transplants for life-enhancement as well as the traditional lifesaving. The table at the right lists the most commonly transplanted tissues (except blood). The various tissues present the surgeon with different challenges. For example, failure of liver transplants is more often due to vascular complications and blood seepage than from rejection. Graft vs. host disease Most bone marrow transplants are done on patients who are immune deficient, either naturally (eg, a genetic defect) or artificially (eg, cytotoxic drug and radiation treatment of cancer). This means the patient does not have a functioning immune system to reject the transplant. However, the transplant does contain immunologically competent cells to reject the recipient! This situation is called graft vs. host disease (GvH) and is probably the greatest problem in the use of bone marrow transplants, affecting 50-70% of marrow recipients. Stimulated Th1 cells produce cytokines that generate inflammatory reactions in the skin, liver, and GI tract. It can lead to liver failure and GI hemorrhage. Promising efforts are being made to "purge" the donor bone marrow of T cells, so they are not available to attack the host. However, some evidence shows that a low level GvH may be beneficial in some situations. In artificially immunosuppressed individuals, a few donor lymphocytes may overwhelm any remaining host T cells and prevent graft rejection.

64. Graft Versus Host Disease Decoste AD, et al., Transfusionassociated graft-vs-host disease in patients with malignancies. Report of two cases and review of the literature. http://www.bchealthguide.org/kbase/nord/nord840.htm

document.write(''); var hwPrint=1; var hwDocHWID="nord840"; var hwDocTitle="Graft versus Host Disease"; var hwRank="1"; var hwSectionHWID="nord840"; var hwSectionTitle=""; var hwSource="cn6.0"; var hwProdCfgSerNo="wsh_html_031_s"; var hwDocType="NORD"; National Organization for Rare Disorders, Inc. Graft versus Host Disease Important It is possible that the main title of the report is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. Synonyms GVHD Disorder Subdivisions Acute GVHD Chronic GVHD Related Disorders List Information on the following diseases can be found in the Related Disorders section of this report: Ulcerative Colitis Lichen Planus General Discussion Graft versus Host Disease (GVHD) is a rare disorder that can strike persons whose immune system is suppressed and have either received a blood transfusion or a bone marrow transplant. Symptoms may include skin rash, intestinal problems similar to colitis, and liver dysfunction. Symptoms The most frequent signs of Graft versus Host Disease (GVHD) occur after a blood transfusion or bone marrow transplant. They are dermatitis (a skin rash), gastrointestinal problems (diarrhea, nausea and abdominal pain) and poor liver function. There may also be involvement of kidneys, lungs, eyes, mouth, musculoskeletal system and heart. GVHD affects about 60% of all bone marrow transplant and transfusion patients whose immune system was suppressed before treatment. Immunosuppression can occur as a result of certain drugs, radiation or certain diseases. Cancer patients and organ transplant recipients often use drugs that suppress their immune systems.

65. R Graft Versus Host Disease . The gvhd data frame has 37 rows and 7 columns. It contains......graft.vs.host {ISwR}, R Documentation. graft versus host disease. http://pbil.univ-lyon1.fr/library/ISwR/html/graft.vs.host.html

66. Print Order Form Graft-versus-Host Disease, 2nd Edition ISBN 1-57059-534-8 This book provides a historical perspective of graftvs-host disease as well as the discussion of the mechanisms involved in graft-vs-host disease. http://www.landesbioscience.com/iu/print_order.php?id=115

67. Johns Hopkins CMM Graduate Program Faculty The immunobiology of bone marrow transplantation and graftvs-host disease Cyclosporine (CsA) is a potent immunosuppressive drug that paradoxically elicits a T http://www.hopkinsmedicine.org/graduateprograms/cmm/hess.html

Allan D. Hess, Ph.D. Professor Department of Oncology Department of Pathology Room 489 Cancer Research Building 410-502-7163 (Fax) adhess@jhmi.edu The immunobiology of bone marrow transplantation and graft-vs-host disease Miura, Y., Thoburn, C. J., Bright, E. C., Sommer, M., Lefell, S., Ueda, M., Nakao, S., and Hess, A. D. , Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven-T-cell response in the development of autologous GVHD. Blood, in press (August), 2001. Hess, A.D. , Thoburn, C.J., Chen, W., and Horwitz, L., Complexity of effector mechanisms in Cyclosporine-induced syngeneic graft-vs-host disease. Biol. Of Blood and Marrow Transplantation, 6:13-24, 2000. Chen, W., Thoburn, C. J., and

68. Wadsworth-GUIDELINES FOR IRRADIATION OF BLOOD AND BLOOD COMPONENTS BACKGROUND. l. Posttransfusion graft-vs-host disease (GVHD) is a serious risk for some severely immunosuppressed or immunodeficient patients. http://www.wadsworth.org/labcert/blood_tissue/irradiate.htm

GUIDELINES FOR IRRADIATION OF BLOOD AND BLOOD COMPONENTS New York State Council on Human Blood and Transfusion Services June 9, 1993 Council on Human Blood and Transfusion Services New York State Department of Health Wadsworth Center for Laboratories and Research P.O. Box 509 Albany, New York 12201-0509 Council Members The New York State Council on Human Blood and Transfusion Services is pleased to provide you with an updated revision of the Guidelines for Irradiation of Blood and Blood Components. These guidelines were developed by the Transfusion Practices Committee and approved by the Council on June 9, 1993. They reflect currently accepted practice as determined by the Council and its committees. The Council is most grateful to those individuals who devoted time and effort to development of these guidelines. Additional copies may be obtained from the State Blood Resources Program at (518) 473-0215. The council would appreciate any comments you may have regarding these guidelines as well as suggestions for topics for future consideration. Please direct correspondence to: Dr. Jeanne Linden, Executive Secretary

69. Methodist Healthcare System physician with the Texas Transplant Institute, shows promising results in treating transplant patients’ steroidresistant graft vs. host disease (GVHD) with http://media.sahealth.com/viewpressrelease.asp?MediaID=479

70. Center News -- TEMPLATE-- 12/21/00 CENTER NEWS THURS., DEC. 21, 2000, SCIENCE SPOTLIGHT. Nuvion fights severe graft-vs.-host disease in phase I trial. By SUSAN EDMONDS. http://www.fhcrc.org/pubs/center_news/2000/Dec21/nuvion.sht

SUBSCRIBE HEADLINE NEWS Anti-smoking trial fails to prevent teen smoking Weather notifications via e-mail OFF THE TOP Flu vaccine now available to all HUTCH FACTS How many miles of aluminum foil does SR go through each year? Day Campus holiday light display resumes First-class postage rates to jump Starfish story underscores patient's holiday gratitude ... Winners abound in Holiday Door Decorating Contest SCIENCE SPOTLIGHT Nuvion fights severe graft-host disease HR NEWS Computer classes HR classes Jobs Employee assistance program EMPLOYEE ADVISORY COMMITTEE Many topics from last EAC meeting COLUMNS Hutch Views: Diverse faculty pace Human Biology WEB WATCH CDC site yields wealth of information DIVISION NOTES Cell-division essay wins Ciosk award Basic Sciences seminar examines biological systems Scholarships go to postdocs/grad students UPDATES Calendar Cafe hours Weather Traffic ... CENTER NEWS - THURS., DEC. 21, 2000 SCIENCE SPOTLIGHT Nuvion fights severe graft-vs.-host disease in phase I trial By SUSAN EDMONDS `We are encouraged by the preliminary efficacy seen with Nuvion to date.'

71. Center News - 1/8/04 - Genetic Test Creates Prediction recipients with a common variant of an immunesystem regulator gene are half as likely as other patients to develop clinically severe graft-vs.-host disease. http://www.fhcrc.org/pubs/center_news/2004/jan8/sart2.html

@import "/wrapper/fhcrc.css"; HOME Visitor Center Publications Center News ... Credits Resources Employee Calendar Scientific Seminars Classes Center Classifieds ... Search Center News Archive Science Article January 8, 2004 The outcome is in the genes Clinical Research Division study reveals a genetic difference that predicts the likelihood of severe transplant complication Drs. John Hansen and Ming-Tseh Lin have developed a genetic test for predicting transplant outcome that may help doctors choose the best treatment plan for patients. By BARBARA BERG A simple genetic test could help doctors predict the likelihood that a patient will develop a potentially life-threatening complication after a bone-marrow or stem-cell transplant. New research conducted by Drs. Ming-Tseh Lin, John Hansen and colleagues in the Clinical Research Division and Taiwan reveals that transplant recipients with a common variant of an immune-system regulator gene are half as likely as other patients to develop clinically severe graft-vs.-host disease. The complication occurs when transplanted cells mount a destructive immune reaction against a patient's body. The findings, published in the Dec. 4 issue of the New England Journal of Medicine, suggest that inclusion of the genetic test in a patient's standard pre-transplant evaluation could ultimately help doctors determine the optimum timing and course of treatment.

72. Targeting The Signaling Molecule, LAT, For Preventing Graft-vs.-host Disease Targeting the signaling molecule, LAT, for preventing graftvs.-host disease . Funding Funding Leukemia Research Foundation. Principal Investigator http://www.surgery.wisc.edu/transplant/research/grant_mmh_lrf.shtml

"Targeting the signaling molecule, LAT, for preventing graft-vs.-host disease " Funding: Funding: Leukemia Research Foundation Principal Investigator: Majed M. Hamawy, Ph.D. Lab Website: (Lab website not available at this time) Project Summary: Administration Maps Affiliated Hospitals Med Student Information ... University of Wisconsin Department of Surgery First published: 07/15/02 Last updated : webmaster@surgery.wisc.edu

73. Save On Health Books Concerning Graft Versus Host Disease Dermatology) Julian L. Verbov / Hardcover / Published 1987. graftvs.-host disease James LM Ferrara(editor), Et Al / Hardco Ver / Published 1996. http://www.healthlinkusa.com/bookpage/129_1.html

74. ARIAD Pharmaceuticals Investor Relations ARIAD Announces New ClinicalScale Production Methods for Its graft-vs-host disease Product Candidate; Patients Undergoing Bone Marrow and Stem Cell http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=aria&script=460&layout=-6

75. Lab News, Dec 2000e, Department Of Laboratory Medicine At Yale Transfusion Associated graftvs-host disease and Irradiation of Blood Components (Part I). graft-vs-host-disease (GVHD), results http://info.med.yale.edu/labmed/labnews/dec2000e.html

Medical and Undergraduate Student Opportunities Yale School of Medicine Courses Medical Technologist Training Yale PA Program ... Symposiums/Clubs/Conferences/Lectures LAB NEWS December 2000 . . . . . . . . . . Vol. 40 No. 1 Chairman: Peter Jatlow, MD Editor: Edward L. Snyder, MD Production Assistant: Marilyn Moran Contributors: Li Chai, MD;Richard K. Donabedian, MD; Stephen Edberg, PhD, ABMM; Barbara Kinder; MD; Marie Louise Landry; Gregory Pomper, MD; Brian R. Smith, MD; Richard Torres; MD; Sanjivi Wadhwa; Marissa Wilck, MD Transfusion Associated Graft-vs-Host Disease and Irradiation of Blood Components (Part I). IMMUNE AND PATHOPHYSIOLOGIC MECHANISMS The dosage of immunocompetent cells transfused is also believed to be important in the development of GVHD. Based on animal studies, a minimum dose of 1x10 cells per kg body weight is necessary to induce a "runting syndrome" and case studies suggest that a similar threshold is necessary to produce GVHD in man. There have been reports of fatal TA-GVHD, however, occurring in children with severe combined immunodeficiency in which a dose of only 8x104 lymphocytes per kg body weight appeared to be transfused. The threshold number of viable cells necessary to produce a graft-versus-host reaction, therefore, may vary depending upon the immune status of the host as well as the antigenic similarity, or disparity between the donor and the recipient.

76. University Of Virginia Patent Foundation Biotechnology Therapeutics. Transplant antigens for graftvs-host disease. Goulmy, Engelhard, Hunt HA-1 and HA-2 antigenic peptides The http://www.uvapf.org/technologies/index.cfm/fuseaction/invention/invention_id/27

MAIN ABOUT RESOURCES TECHNOLOGIES ... CONTACT June 9,2004 Available Technologies : Medical and Biotechnology Therapeutics Transplant antigens for graft-vs-host disease HA-1 and HA-2 antigenic peptides The present invention discloses peptide sequences of a so called minor H antigen. The minor H antigens are associated with the Graft-versus-Host Disease. The peptides and their derivatives find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. One of the peptides is derived from the HA-2 minor antigen and has the sequence YXGEVXVSV, wherein X represents a leucine or an isoleucine residue. The other peptide is derived from the HA-1 minor antigen. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants. US Patent No. 5,770,201 describes the HA-2 antigen; both antigens are co-owned with the University of Leiden. U. Leiden can license these rights on behalf of both parties. The Patent Foundation can provide contact information.

77. Study Focuses On Reduced-Intensity Stem Cell Transplant Protocol Another serious problem following stem cell transplants is patients developing graftvs.-host disease (GVHD), an immune attack of recipient organs by donor http://www.stlouischildrens.org/articles/professional.asp?ID=4107

78. Graft Versus Host Disease,: CD4+ T Cells Mediate Syngeneic Graft-versus-host Dis According to a study from the United States, Syngeneic graftvs-host disease (SGVHD) develops following lethal irradiation, reconstitution with syngeneic bone http://www.obgyn.net/newsheadlines/headline_medical_news-Graft_versus_Host_Disea

HEADLINE NEWS subscribe by email - Featured Sections - Breast Care Chronic Pelvic Pain Contraception Endometriosis Pavilion EndoZone Fetal Monitoring Gynecological Oncology Infertility Menopause Nursing Osteoporosis PCOS Physicians-in-Training PMS/PMDD Technology Ultrasound Urogynecology Weight Management Young Woman Home Medical Professionals Women's Pavilion Industry Professionals Forums Asia Europe Latina Country Pages Sign up for OBGYN.net e-mail Newsletters Career Search Site Update Free Email Newsletter Daily News Quick Links Acronym Expander Bibliography Bookstore Member Webpages ... PowerPoint Presentations Practice Tools Build your own web page Employment Opportunities Find a CV Medical Web Sites ... Image Library Conference Calendar OB-GYN Calendar OB-GYN Upcoming Meetings Conference Coverage Conference Interviews Book of Proceedings from COGI 99 Medical Resources Academic Departments of OBGYN Academic Links Acronyms Explained Associations and Societies ... Student Resources News and Views Free Email Newsletter Today's News Media Page Vendor Directory Add your company Search Equipment Pharmaceutical ... Supplies Global Latina Europe Country Pages U. S. Information

79. Research Project Graft-vs.-host En Graft-vs.-leukemia-effect Of Donor Lymphoc .. graftvs.-host en graft-vs.-leukemia-effect of donor lymphocyte infusions in murine models of In most cases however also in a graft versus host disease. http://www.kuleuven.ac.be/research/researchdatabase/project/3M03/3M030167.htm

Home Research activities Research groups Key domains ... Nederlands K.U.Leuven IWETO-researchdatabase Research project Person in charge of the project: WAER MARK , member of research team Nephrology Section Title: Graft-vs.-host en graft-vs.-leukemia-effect of donor lymphocyte infusions in murine models of allogeneic bone marrow transplanta- tion.... Project summary: Donor leucocyte injection results after bone marrow transplantation in a graft versus leucemia effect. In most cases however also in a graft versus host disease. In this project it is investigated how both effect can be separated. Project number: Duration of the project: Funded research Nederlands Christelle Maeyaert Most recent update :01.03.2004 URL: http://www.kuleuven.ac.be/research/researchdatabase/project/3M03/3M030167.htm

80. Humana Press Complications of Transplantation Pathophysiology of Acute graftvs-host disease Takanori Teshima and James LM Ferrara Acute graft-vs-host disease Uwe http://www.humanapress.com/ProductDetail.pasp?txtCatalog=HumanaBooks&txtCategory

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 4     61-80 of 90    Back | 1  | 2  | 3  | 4  | 5  | Next 20